Protocadherin-10 acts as a tumor suppressor gene, and is frequently downregulated by promoter methylation in pancreatic cancer cells

Qiu,Chan; Bu,Xiaona; Jiang,Zheng

doi:10.3892/or.2016.4793

Protocadherin-10 acts as a tumor suppressor gene, and is frequently downregulated by promoter methylation in pancreatic cancer cells

Authors:
- Chan Qiu
- Xiaona Bu
- Zheng Jiang
View Affiliations

Affiliations: Department of Gastroenterology, First Affiliated Hospital, Chongqing Medical University, Chongqing 400016, P.R. China
Published online on: May 9, 2016 https://doi.org/10.3892/or.2016.4793
Pages: 383-389

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Protocadherin-10 (PCDH10), a member of non-clustered protocadherin family which plays important roles in calcium-dependent cell-cell signal transduction and adhesion. PCDH10 functions as a tumor suppressor gene and its expression is downregulated by promoter methylation in many malignances. In the present study, we explored PCDH10 expression and promoter methylation status, and its biological effects in pancreatic cancer cells, and furthermore, we explored the mechanism of PCDH10 preliminary in pancreatic cancer cells. the mRNA level of PCDH10 was detected by semi-quantitative reverse transcription PCR and promoter methylation status examined by methylation-specific PCR in the pancreatic cancer cells (Capan-1, Panc-1, AsPC-1 and BxPC-3) as well as the human normal pancreatic ductal epithelial cells HPDE6-C7 which was used as a control. The human pancreatic cells were transfected with plasmid pcDNA3.1-PCDH10 or pcDNA3.1 by lipofectamine 2000. The biological function of PCDH10 in pancreatic cancer cells was determined by CCK-8 assay, colony formation assay, flow cytometry, Transwell invasion assay and wound-healing assay. The levels of apoptosis related proteins were examined by western blotting. PCDH10 expression was obviously downregulated in the pancreatic cancer cells (Capan-1, Panc-1, BxPC-3) compared to the normal pancreatic ductal epithelial cells. PCDH10 promoter methylation was observed in the two pancreatic cancer cells Capan-1 and BxPC-3,and the expression of PCDH10 could be restored after treating with 5-aza-2’-deoxycytidine and trichostatin A in the two cell types. Overexpression of PCDH10 can inhibit the proliferation, migration, invasion ability of pancreatic cancer cells and induce apoptosis. Ectopic expression of PCDH10 could increase the levels of PARP, caspase-3, caspase-9 and decrease the level of bcl-2, AKT and p-AKT. PCDH10 acts as a tumor suppressor gene, and is frequently down-regulated by promoter methylation in pancreatic cancer cells. PCDH10 may induce cancer cell apoptosis via the AKT pathway.

View Figures

View References

1	Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T and Thun MJ: Cancer statistics, 2008. CA Cancer J Clin. 58:71–96. 2008. View Article : Google Scholar : PubMed/NCBI
2	Hong SM, Park JY, Hruban RH and Goggins M: Molecular signatures of pancreatic cancer. Arch Pathol Lab Med. 135:716–727. 2011.PubMed/NCBI
3	Wolffe AP and Matzke MA: Epigenetics: Regulation through repression. Science. 286:481–486. 1999. View Article : Google Scholar : PubMed/NCBI
4	Singal R and Ginder GD: DNA methylation. Blood. 93:4059–4070. 1999.PubMed/NCBI
5	Esteller M: Cancer epigenomics: DNA methylomes and histone-modification maps. Nat Rev Genet. 8:286–298. 2007. View Article : Google Scholar : PubMed/NCBI
6	Merlo A, Herman JG, Mao L, Lee DJ, Gabrielson E, Burger PC, Baylin SB and Sidransky D: 5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat Med. 1:686–692. 1995. View Article : Google Scholar : PubMed/NCBI
7	Xiang T, Li L, Yin X, Yuan C, Tan C, Su X, Xiong L, Putti TC, Oberst M, Kelly K, et al: The ubiquitin peptidase UCHL1 induces G0/G1 cell cycle arrest and apoptosis through stabilizing p53 and is frequently silenced in breast cancer. PLoS One. 7:e297832012. View Article : Google Scholar : PubMed/NCBI
8	Li L, Ying J, Tong X, Zhong L, Su X, Xiang T, Shu X, Rong R, Xiong L, Li H, et al: Epigenetic identification of receptor tyrosine kinase-like orphan receptor 2 as a functional tumor suppressor inhibiting β-catenin and AKT signaling but frequently methylated in common carcinomas. Cell Mol Life Sci. 71:2179–2192. 2014. View Article : Google Scholar
9	Redies C, Vanhalst K and Roy F: Delta-Protocadherins: Unique structures and functions. Cell Mol Life Sci. 62:2840–2852. 2005. View Article : Google Scholar : PubMed/NCBI
10	Morishita H and Yagi T: Protocadherin family: Diversity, structure, and function. Curr Opin Cell Biol. 19:584–592. 2007. View Article : Google Scholar : PubMed/NCBI
11	Yu JS, Koujak S, Nagase S, Li CM, Su T, Wang X, Keniry M, Memeo L, Rojtman A, Mansukhani M, et al: PCDH8, the human homolog of PAPC, is a candidate tumor suppressor of breast cancer. Oncogene. 27:4657–4665. 2008. View Article : Google Scholar : PubMed/NCBI
12	Hu X, Sui X, Li L, Huang X, Rong R, Su X, Shi Q, Mo L, Shu X, Kuang Y, et al: Protocadherin 17 acts as a tumour suppressor inducing tumour cell apoptosis and autophagy, and is frequently methylated in gastric and colorectal cancers. J Pathol. 229:62–73. 2013. View Article : Google Scholar
13	Lv J, Zhu P, Yang Z, Li M, Zhang X, Cheng J, Chen X and Lu F: PCDH20 functions as a tumour-suppressor gene through antagonizing the Wnt/β-catenin signalling pathway in hepatocellular carcinoma. J Viral Hepat. 22:201–211. 2015. View Article : Google Scholar
14	Li Z, Chim JC, Yang M, Ye J, Wong BC and Qiao L: Role of PCDH10 and its hypermethylation in human gastric cancer. Biochim Biophys Acta. 1823:298–305. 2012. View Article : Google Scholar
15	Zhong X, Zhu Y, Mao J, Zhang J and Zheng S: Frequent epigenetic silencing of PCDH10 by methylation in human colorectal cancer. J Cancer Res Clin Oncol. 139:485–490. 2013. View Article : Google Scholar
16	Tang X, Yin X, Xiang T, Li H, Li F, Chen L and Ren G: Protocadherin 10 is frequently downregulated by promoter methylation and functions as a tumor suppressor gene in non-small cell lung cancer. Cancer Biomark. 12:11–19. 2013.PubMed/NCBI
17	Ying J, Li H, Seng TJ, Langford C, Srivastava G, Tsao SW, Putti T, Murray P, Chan AT and Tao Q: Functional epigenetics identifies a protocadherin PCDH10 as a candidate tumor suppressor for nasopharyngeal, esophageal and multiple other carcinomas with frequent methylation. Oncogene. 25:1070–1080. 2006. View Article : Google Scholar
18	Redston MS, Caldas C, Seymour AB, Hruban RH, da Costa L, Yeo CJ and Kern SE: p53 mutations in pancreatic carcinoma and evidence of common involvement of homocopolymer tracts in DNA microdeletions. Cancer Res. 54:3025–3033. 1994.PubMed/NCBI
19	Yi JM, Guzzetta AA, Bailey VJ, Downing SR, Van Neste L, Chiappinelli KB, Keeley BP, Stark A, Herrera A, Wolfgang C, et al: Novel methylation biomarker panel for the early detection of pancreatic cancer. Clin Cancer Res. 19:6544–6555. 2013. View Article : Google Scholar : PubMed/NCBI
20	Roperch JP, Incitti R, Forbin S, Bard F, Mansour H, Mesli F, Baumgaertner I, Brunetti F and Sobhani I: Aberrant methylation of NPY, PENK, and WIF1 as a promising marker for blood-based diagnosis of colorectal cancer. BMC Cancer. 13:5662013. View Article : Google Scholar : PubMed/NCBI
21	Balgkouranidou I, Matthaios D, Karayiannakis A, Bolanaki H, Michailidis P, Xenidis N, Amarantidis K, Chelis L, Trypsianis G, Chatzaki E, et al: Prognostic role of APC and RASSF1A promoter methylation status in cell free circulating DNA of operable gastric cancer patients. Mutat Res. 778:46–51. 2015. View Article : Google Scholar : PubMed/NCBI
22	Schutte M, Hruban RH, Geradts J, Maynard R, Hilgers W, Rabindran SK, Moskaluk CA, Hahn SA, Schwarte-Waldhoff I, Schmiegel W, et al: Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas. Cancer Res. 57:3126–3130. 1997.PubMed/NCBI
23	Yu J, Cheng YY, Tao Q, Cheung KF, Lam CN, Geng H, Tian LW, Wong YP, Tong JH, Ying JM, et al: Methylation of protocadherin 10, a novel tumor suppressor, is associated with poor prognosis in patients with gastric cancer. Gastroenterology. 136:640–51.e1. 2009. View Article : Google Scholar
24	Jao TM, Tsai MH, Lio HY, Weng WT, Chen CC, Tzeng ST, Chang CY, Lai YC, Yen SJ, Yu SL, et al: Protocadherin 10 suppresses tumorigenesis and metastasis in colorectal cancer and its genetic loss predicts adverse prognosis. Int J Cancer. 135:2593–2603. 2014. View Article : Google Scholar : PubMed/NCBI
25	Xu Y, Yang Z, Yuan H, Li Z, Li Y, Liu Q and Chen J: PCDH10 inhibits cell proliferation of multiple myeloma via the negative regulation of the Wnt/β-catenin/BCL-9 signaling pathway. Oncol Rep. 34:747–754. 2015.PubMed/NCBI
26	Li Z, Yang Z, Peng X, Li Y, Liu Q and Chen J: Nuclear factor-κB is involved in the protocadherin-10-mediated pro-apoptotic effect in multiple myeloma. Mol Med Rep. 10:832–838. 2014.PubMed/NCBI
27	Degterev A and Yuan J: Expansion and evolution of cell death programmes. Nat Rev Mol Cell Biol. 9:378–390. 2008. View Article : Google Scholar : PubMed/NCBI
28	Indran IR, Tufo G, Pervaiz S and Brenner C: Recent advances in apoptosis, mitochondria and drug resistance in cancer cells. Biochim Biophys Acta. 1807:735–745. 2011. View Article : Google Scholar : PubMed/NCBI
29	Drel' VR, Shymans'kyĭ IO, Sybirna NO and Velykyĭ MM: Role of PARP and protein poly-ADP-ribosylation process in regulation of cell functions. Ukr Biokhim Zh. 83:5–34. 2011.
30	Fuchs Y and Steller H: Programmed cell death in animal development and disease. Cell. 147:742–758. 2011. View Article : Google Scholar : PubMed/NCBI
31	Hers I, Vincent EE and Tavaré JM: Akt signalling in health and disease. Cell Signal. 23:1515–1527. 2011. View Article : Google Scholar : PubMed/NCBI
32	Manning BD and Cantley LC: AKT/PKB signaling: Navigating downstream. Cell. 129:1261–1274. 2007. View Article : Google Scholar : PubMed/NCBI